Generics pharmaceutical company Krka is celebrating its 70th anniversary since it launched its first human pharmaceuticals laboratory and over 50 years supporting animal health. This milestone year is also marked by the company’s first Environmental, Social and Governance (ESG) rating being awarded at the end of 2023, placing it in the top 10% of pharmaceutical companies accredited by ESG rating auditor S&P Global.
The rating success, says the firm, reflects Krka’s ever-increasing focus on sustainability from the early 2000s with initiatives implemented since 2018 resulting in over 50 million euros being invested in environmental protection. The company continues its strategic plan to further reduce its carbon footprint, with key targets set for 2025, 2030 and 2050.
Charlotte Read, Krka UK sales manager, comments: “Krka has grown significantly in recent years and we are immensely proud that our reputation for being sustainable and ethical remains steadfast. Since 2019 we have recorded a 48% decrease in CO2 emissions which just shows that a lot can still be achieved by our wider environmental and social responsibilities being integral to the company’s day-to-day operations. As we entered our 70th birthday year, a top ESG rating was the icing on the cake and we were delighted to celebrate this achievement at the BVA Live event in June.”
Since its inception in 1954, Krka says, it has focused on production quality and efficiency and this approach has also driven positive impacts for environmental protection; of particular note is the benefit of Krka’s manufacturing system which, “as a complete end-to-end process from the active pharmaceutical ingredient (API) to final product, brings not only benefits to quality control and operational efficiency, but also optimises product miles to reduce carbon footprint”.
Comments